State of New Jersey Common Pension Fund D Has $2.27 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

State of New Jersey Common Pension Fund D lessened its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 42.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 113,607 shares of the biotechnology company's stock after selling 84,249 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in ADMA Biologics were worth $2,271,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Sigma Planning Corp bought a new position in shares of ADMA Biologics in the third quarter valued at about $300,000. Hollencrest Capital Management acquired a new stake in ADMA Biologics during the third quarter worth approximately $30,000. Principal Financial Group Inc. boosted its holdings in shares of ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after acquiring an additional 1,059,394 shares during the period. Amalgamated Bank increased its stake in shares of ADMA Biologics by 803.0% during the third quarter. Amalgamated Bank now owns 68,169 shares of the biotechnology company's stock worth $1,363,000 after purchasing an additional 60,620 shares during the period. Finally, Roman Butler Fullerton & Co. boosted its stake in ADMA Biologics by 241.6% in the 3rd quarter. Roman Butler Fullerton & Co. now owns 107,626 shares of the biotechnology company's stock valued at $2,151,000 after purchasing an additional 76,121 shares during the period. Institutional investors own 75.68% of the company's stock.

Insider Activity

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares of the company's stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares of the company's stock, valued at $36,436,552.94. This represents a 10.31 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,900 shares of company stock valued at $8,224,121. Insiders own 3.70% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. HC Wainwright lifted their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Raymond James raised their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th.

ADMA Biologics Price Performance

Shares of ADMA traded down $0.98 during trading hours on Friday, reaching $19.22. The stock had a trading volume of 2,028,167 shares, compared to its average volume of 3,659,861. The stock has a market capitalization of $4.48 billion, a PE ratio of 72.14 and a beta of 0.64. ADMA Biologics, Inc. has a 12 month low of $3.60 and a 12 month high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company's 50-day moving average is $18.42 and its two-hundred day moving average is $14.22.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the firm posted $0.01 earnings per share. Research analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.